Clinical TrialJul 15, 2026, 08:01 AM
Rani Therapeutics RT-114 Phase 1a Data Shows >150% Bioavailability
AI Summary
Rani Therapeutics reported positive initial Phase 1a data for RT-114, an orally administered GLP-1/GLP-2 dual agonist. The study demonstrated that oral RT-114 achieved systemic exposure and bioavailability greater than 150% compared to a matched subcutaneous dose of PG-102, with a favorable safety and tolerability profile. The company is expanding the Phase 1a study to further characterize the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity, expected to start in 2026 with data in 2027.
Key Highlights
- Oral RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102.
- Bioavailability of oral RT-114 was greater than 150% relative to a matched 12 mg subcutaneous dose of PG-102.
- No adverse events were attributed to the RaniPill Capsule itself.
- Treatment-related adverse events were mild, transient, and consistent with GLP-1/GLP-2 dual agonists.
- Elimination half-life was similar: 5.6 days for oral RT-114 versus 5.3 days for subcutaneous PG-102.
- Phase 1a study expanded with an additional cohort of 15 healthy volunteers to further define pharmacokinetics.
- Phase 1b repeat-dose study in patients with obesity is expected to begin in 2026.
- Data from the Phase 1b study is anticipated in 2027.
Price Impact
More from RANI